Protocol Ledger

NCT04317534 · Phase II · RECRUITING

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Interventional Phase II clinical trial protocol NCT04317534 sponsored by Greg Durm, MD in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-05-05 Enrollment: 244 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04317534
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)244 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04317534
Protocol FieldVerified Registry Value
NCT IdentifierNCT04317534
Consolidated Lead SponsorGreg Durm, MD
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment244 participants (ESTIMATED)
Registered Start Date2020-05-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI